Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease

ObjectiveThis study evaluated short- and long-term efficacy and safety of the second-generation somatostatin receptor ligand pasireotide alone or in combination with dopamine agonist cabergoline in patients with Cushing’s disease (CD).Study designThis is an open-label, multicenter, non-comparative,...

Full description

Bibliographic Details
Main Authors: Richard A. Feelders, Maria Fleseriu, Pinar Kadioglu, Marie Bex, Deyanira González-Devia, Cesar Luiz Boguszewski, Dilek Gogas Yavuz, Heather Patino, Alberto M. Pedroncelli, Ricardo Maamari, Arghya Chattopadhyay, Beverly M. K. Biller, Rosario Pivonello
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Endocrinology
Subjects:
somatostatin
pasireotide
cabergoline
Cushing’s disease
hypercortisolism
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2023.1165681/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2023.1165681/full

Similar Items